Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M)

What Was Tested

This randomized controlled trial paper looks at Lixisenatide.

Who Took Part

According to the abstract, 680 patients were involved.

The age groups tagged for this paper are middle-aged adults, both men and women.

Patients were randomized to lixisenatide morning (n = 255), lixisenatide evening (n = 255), placebo morning (n = 85), or placebo evening (n = 85) injections.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The patients were allocated by chance, so the Lixisenatide group and the comparison group should start out alike.

Blinding on both sides kept the patients and researchers unaware of who received Lixisenatide.

Some patients received a placebo instead of Lixisenatide, giving a reference point.

What Was Measured

Topics PubMed links to this paper include Blood Glucose, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Metformin, Peptides and Glucagon-Like Peptide-2 Receptor.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Lixisenatide in 680 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2013 (Diabetes care), a journal based in United States.

More context: the Lixisenatide compound page, all human trials.